Unknown

Dataset Information

0

Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35?h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.


ABSTRACT: BACKGROUND:Ovarian hyperstimulation syndrome remains a serious complication during in vitro fertilization cycles if high dose human chorionic gonadotropin (hCG) is used to trigger ovulation in high responder patients. Though much of this risk is mitigated with trigger using gonadotropin releasing-hormone (GnRH) agonist alone, it may result in lower birth rates. GnRH-agonist trigger and adjuvant low dose hCG has been proposed to improve birth rates, but timing of this hCG support to corpus luteum function has never been fully described. In this randomized, prospective trial, we explore differences in live birth rates and incidence of ovarian hyperstimulation syndrome (OHSS) in high-responder patients undergoing in vitro fertilization (IVF) receiving low dose hCG at the time of GnRH-agonist (dual trigger) or hCG adjuvant at the time of oocyte retrieval. Does the timing of hCG support make a difference? RESULTS:Thirty-four subjects high-responder patients were randomized to receive low-dose hCG at the time of GnRH-agonist trigger (Group 1) and 37 received low-dose hCG at the time of oocyte retrieval (Group 2). There were no differences in the baseline characteristics and outcome of ovarian stimulation between the two groups. There were no differences in the live birth rates between Group 1 and Group 2 by intention-to-treat (14/34, 41.2% versus 21/37, 56.8%, p?=?0.19) or per-protocol (14/26, 53.8% versus 19/31, 61.3%, p?=?0.57) analyses. There was a slightly higher incidence of OHSS in Group 2 compared to Group 1 although the difference was not statistically significant (3/31, 9.7% versus 1/26, 3.8%). All the cases of OHSS in Group 2 were moderate while the one case of OHSS in Group 1 was mild. CONCLUSIONS:For high responder patients receiving GnRH-agonist trigger, low dose hCG supplementation allowed high pregnancy rates after fresh embryo transfer, regardless of whether it was given at the time of trigger or at oocyte retrieval. Dual trigger may be preferable to reduce the risk of OHSS.

SUBMITTER: Engmann LL 

PROVIDER: S-EPMC6347742 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.

Engmann L L LL   Maslow B S BS   Kaye L A LA   Griffin D W DW   DiLuigi A J AJ   Schmidt D W DW   Grow D R DR   Nulsen J C JC   Benadiva C A CA  

Journal of ovarian research 20190126 1


<h4>Background</h4>Ovarian hyperstimulation syndrome remains a serious complication during in vitro fertilization cycles if high dose human chorionic gonadotropin (hCG) is used to trigger ovulation in high responder patients. Though much of this risk is mitigated with trigger using gonadotropin releasing-hormone (GnRH) agonist alone, it may result in lower birth rates. GnRH-agonist trigger and adjuvant low dose hCG has been proposed to improve birth rates, but timing of this hCG support to corpu  ...[more]

Similar Datasets

| S-EPMC6499926 | biostudies-literature
| S-EPMC6715633 | biostudies-literature
| S-EPMC5545220 | biostudies-other
| S-EPMC5541180 | biostudies-other
| S-EPMC4531869 | biostudies-literature
| S-EPMC3727944 | biostudies-literature
| S-EPMC10925639 | biostudies-literature
| S-EPMC5445054 | biostudies-literature
| S-EPMC4096878 | biostudies-literature
| S-EPMC8551612 | biostudies-literature